This paper argues that randomization should more often be considered for early trials of experimental cancer treatments. Uncontrolled as well as randomized designs for Phase II trials are reviewed. The severe limitations of uncontrolled designs are illustrated, and possible difficulties with randomized designs discussed. It is argued that in randomized Phase II trials, the treatment allocation method should be chosen to achieve good balance with respect to the most important prognostic factors.
RetainMJMickRSchilskyRLSieglerM.Statistical and ethical issues in the design and conduct of Phase I and II clinical trials of new anticancer agents. J Natl Cancer Instit.1993;85:1637–1643.
2.
StorerBDeMetsD.Current Phase I/II designs: are they adequate?J Clin Research and Drug Dev.1987;1:121–130.
3.
MickRLaneNFaughertyCRatainMJPhysician-determined patient risk of toxic effects: impact on enrollment and decision making in Phase I cancer trials. J Natl Cancer Instit.1994;86:1685–1693.
4.
DurhamSDFlournoyNRosenbergerWFA random walk rule for Phase I clinical trials. Biometrics.1997;53:745–760.
5.
MarsoniSHothDSimonRLeyland-JonesBde RosaMWittesREClinical drug development: an analysis of Phase II trials, 1970–1985. Cancer Treat Rep.1987;71:71–80.
6.
World Health Organization.WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva: World Health Organization; 1979.
7.
GehanEAThe determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis.1961;13:346–353.
8.
FlemingTROne-sample multiple testing procedures for Phase II clinical trials. Biometrics.1982;38:143–151.
9.
SimonR.Optimal two-stage designs for phase II clinical trials. Control Clin Trials.1989;10:1–10.
10.
PouillartPFumoleauPRomieuGFinal results of a Phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer. Proc ASCO.1999;18:73a (Abstract #275).
11.
HersonJ.Statistical aspects in design and analysis of Phase II clinical trials. In: BuyseMEStaquetMJSylvesterRJ (eds), Cancer Clinical Trials. Methods and Practice.Oxford: Oxford University Press; 1985: pp 239–257.
12.
MoertelCGSchuttAIHahnRGReitemeierRSEffects of patient selection on results of Phase II chemotherapy trials in gastrointestinal cancer. Cancer Chemother Rep.1974;58:257–260.
13.
WilkePBuyseMPignonJPCritical issues in colorectal cancer trial design. In: Management of Colorectal Cancer.BleibergHRougierPPiedboisHT, eds. London: Martin Dunitz Publishers; 1997:375–386.
14.
WadlerSSchwartzELGoldmanMFluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol.1995;7:1769–1775.
15.
RadererMScheithauerW.Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: an overview of clinical trials. Eur J Cancer.1995; 31A:1002–1008.
16.
GrecoFAFiglinRYorkMPhase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol.1996;10:2674–2681.
17.
Corfu-A Study Group.Phase III randomized study of two flouorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol.1995;13:921–928.
18.
GehanEAFreireichEJNon-randomized controls in cancer trials. N Engl J Med.1974;290:198–203.
19.
SimonRWittesREEllenbergSSRandomized Phase II clinical trials. Cancer Treat Rep.1985;69: 1375–1381.
20.
FisherBRocketteHRobidouxAEffect of preoperative therapy for breast cancer on locoregional disease: first report of NSABP-18. Proc ASCO.1994;13:64 (Abstract 57).
21.
LiuPYLeBlancMDesaiM.False positive rates of randomized Phase II designs. Control Clin Trials.1999;20:343–352.
22.
HersonICarterSKCalibrated Phase II clinical trials in oncology. Stat Med.1986;5:441–447.
23.
LeichmanCGFlemingTRMuggiaFMPhase I study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol.1995;13:1303–1311.
24.
Advanced Colorectal Cancer Meta-Analysis Project.Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol.1992;10:896–903.
25.
Meta-Analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol.1998;16:301–308.
26.
RoyalRMEthics and statistics in randomized clinical trials (with discussion). Stat Science.1991;6: 52–88.
27.
ChalmersTCSymposium on diseases of the liver: randomization of the first patient. Med Clin N Am.1975;59:1035–1037.
28.
ChalmersI.Report of meeting of open section. J Royal Soc Med.1990;83:337–339.
29.
BuyseM.Potential and pitfalls of randomized clinical trials in cancer research. Cancer Surveys.1989;8:91–105.
30.
KalishLABeggCBTreatment allocation methods in clinical trials: a review. Stat Med.1985;4:129–144.
31.
SimonR.Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep.1984;68:185–192.
32.
TherneauTMHow many stratification factors are “too many” to use in a randomization plan?Control Clin Trials.1993;14:98–108.
33.
PocockSJSimonR: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics.1975;31:103–115.
